1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-05 am EDT
10866.00 GBX   +1.36%
08/06Daiichi Sankyo and AstraZeneca’s Enhertu® Receives Approval in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
CI
08/05ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
BU
08/05ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ASTRAZENECA : UBS is Neutral

06/14/2022 | 01:23am EDT

UBS's analyst Michael Leuchten is no longer positive. The broker's recommendation changes from Buy to Neutral. The target price is lowered from GBX 10500 to GBX 10100.


© MarketScreener with dpa-AFX Analyser 2022
All news about ASTRAZENECA PLC
08/06Daiichi Sankyo and AstraZeneca’s Enhertu® Receives Approval in the U.S. as the Fir..
CI
08/05ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe..
BU
08/05ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/05CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indicat..
BU
08/05AstraZeneca Announces CALQUENCE Tablet Formulation Approved in the US
CI
08/05AstraZeneca's Enhertu wins keenly-anticipated U.S. breast cancer nod
RE
08/05AstraZeneca's Enhertu wins US approval for broader breast cancer use
RE
08/05Calquence tablet formulation approved in the US across current indications
AQ
08/05AstraZeneca Says FDA Approved Tablet Formulation of Calquence Cancer Treatment
MT
08/05US FDA Approves AstraZeneca's Lymphoma Drug Formulation
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 198 M - -
Net income 2022 4 471 M - -
Net Debt 2022 24 385 M - -
P/E ratio 2022 46,7x
Yield 2022 2,25%
Capitalization 203 B 203 B -
EV / Sales 2022 5,14x
EV / Sales 2023 4,76x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 130,88 $
Average target price 144,30 $
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC25.21%202 796
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-15.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.2.60%244 068